KansasPrescribed does not mean approved

A little clarity before care.

All chapters

Weight medicines and copies

Untangle weight medicines and their copies.

The full product name gives you a place to start. Ask what it contains, who made it and which rule permits it.

Start with the short answer
Follow the question.
  1. Approved productName + pill, injection or other kind
  2. Made-to-order copyAsk why it is allowed for you
  3. Changed ingredientAsk exactly what changed

Take this with you

Words to start the conversation

  • Is this an approved product, an approved generic, or compounded?
  • What is the exact ingredient? Is the medicine a pill, injection or something else?
  • Which current rule permits this medicine to be made for me?

Reconsider the care assumption

The change still has to matter for you.

Federal status as of September 26, 2026; Kansas board guidance as of October 1, 2026.

The Food and Drug Administration (FDA) says semaglutide made with an added vitamin may still count as a copy of an available drug.

The Kansas pharmacy board warns that a prescription with a pre-written reason selected from a checklist may not meet the rules. The pharmacy must keep a record of why the change makes an important difference for each named patient.

Which medicines are being discussed?

Write down the full medicine name and whether it is a pill, injection or something else. Use those details when asking about price, permission to make it or stock.

GLP-1 is a hormone: a natural chemical messenger in your body. It helps control appetite and blood sugar. GLP-1 medicines mimic that hormone’s role in appetite and blood-sugar control.

FDA-approved examples include Ozempic and Wegovy, the brand names for semaglutide, plus Mounjaro and Zepbound, the brand names for tirzepatide.

A generic medicine is an approved counterpart of a brand-name medicine. At the federal date above, no approved and marketable generic of semaglutide or tirzepatide existed.

Another medicine, liraglutide, has approved generic injections, including some approved for weight loss. That does not prove a local pharmacy has stock.

What permits a made-to-order copy

A national shortage is a specific status

A drug shortage is a national FDA listing, rather than an empty shelf at a local pharmacy.

Semaglutide injections and tirzepatide were no longer on the FDA shortage list at the federal date above.

While these drugs were on the national shortage list, the shortage allowed pharmacies to make copies under the compounding rules. That shortage permission has ended for semaglutide injections and tirzepatide. For medicine prepared for a particular named patient, the prescriber must identify a change that makes an important difference to that patient.

For example, FDA describes a need to avoid a dye that causes an allergy. That is a health need; paying less alone is not enough to justify a change. The other compounding rules still apply.

Liraglutide remained on the national shortage list. It cannot be treated as having the same status as the other medicines.

Check the ingredient, not just the name

Here, salt means a chemically altered version of a medicine ingredient. Names such as semaglutide sodium and semaglutide acetate show that change. FDA says these ingredients differ from the one in approved medicines.

The Kansas pharmacy board says these altered salt versions of semaglutide or tirzepatide may not be used in medicines made to order.

Retatrutide and cagrilintide are two unapproved drug ingredients discussed in FDA’s weight-medicine warning. No FDA-approved drug contains either ingredient. FDA has not found either safe to use and shown to help with any condition. FDA says neither can be used to make a compounded medicine under federal law.

Have your prescriber explain which exact medicine they chose, its approval or made-to-order status, and the reason for choosing it.

Request another explanation in plain words if you cannot follow the first one. Keep both the product name and the reason with your notes.

Chapter notes

Evidence for this chapter

  1. A
    FDA: questions about weight drugs

    For altered ingredients such as semaglutide sodium, research labels and ingredients that cannot be made into compounded medicines.

  2. B
    FDA: shortage status and copy rules

    For national supply status and added vitamins.

  3. C
    FDA: approval records

    For the approved products and generic status.

  4. D
    FDA: liraglutide shortage record

    For the different status of liraglutide.

  5. E
    Kansas pharmacy board: compounded weight medicines

    For the state board’s ingredient rules and the record of each patient’s need.